Categories
Politics

Democrats think about new taxes aimed toward CEO pay, inventory buybacks for $3.5 trillion price range plan

Senate Minority Leader Chuck Schumer (D-NY) speaks during a press conference on the coronavirus outbreak at the U.S. Capitol on March 11, 2020 in Washington, DC. Schumer and other members of the Democratic Caucus urged companies and employers to offer all employees paid sick leave in accordance with recommended health practices. Also pictured (LR) are Sen. Sherrod Brown (D-OH), Sen. Ben Cardin (D-MD), Sen. Ron Wyden (D-OR), Sen. Patty Murray (D-WA), Sen. Patrick Leahy (D-VT) and Senator Mark Warner (D-VA).

Win McNamee | Getty Images

Democrats in Congress are considering a series of new taxes to pay their $ 3.5 trillion draft budget, which targets large corporations and the country’s largest corporations to buy back shares.

On a discussion list of several new and expanded potential taxes is a proposal to impose an excise tax on public companies that buy back a “significant” amount of stock.

The list compiled by CNBC also includes a tax on companies whose CEO salaries exceed a ratio to be determined by the average employee of the company.

A discussion list is a draft of ideas that lawmakers put together before formally presenting them to the House or Senate. Members of Congress will often hand out a list to determine which and how many members of the caucus support aspects of the plan. Therefore, important details such as the threshold above which certain taxes would be incurred and the amount of the payment have not yet been clarified.

The Democrats’ plan also includes taxes related to carbon emissions, which would likely be rejected by President Joe Biden and other moderate Democrats.

The proposed carbon taxes include a per tonne tax on the carbon dioxide content of leading fossil fuel manufacturers in production, which starts at $ 15 and escalates over time. Another suggests a per tonne tax on CO2 emissions levied by large industrial emitters such as steel and cement manufacturers. A third offers a simple per barrel tax on crude oil.

A related plan would remove significant fossil fuel tax subsidies, including credits and expedited deductions for extraction, preferential treatment of foreign income, and the ability to evade corporate tax for pipeline companies.

But the supposed taxes are not exclusive to companies.

CNBC policy

Read more about CNBC’s political coverage:

Democrats point out that the current maximum tax rate of 37% will expire by the end of 2025 when it returns to its previous 39.6%. Her plan would speed up that schedule and restore the 39.6% in 2022.

The plan also aims to remove the long-criticized loophole in carried interest by requiring fund managers to pay normal rate taxes annually and be subject to self-employment tax.

Money managers often receive around 20% of accrued profits over a certain annual return, which can constitute the majority of a person’s income if their market bets result in significant profits. But that 20% commission is taxed at the 20% capital gains rate – the Democrats want that income, realized or not, to be taxed at the normal income tax rate every year.

The litany of tax ideas comes as Democrats look for ways to fund major spending initiatives they promised during the 2020 election cycle.

The Biden administration, Senate Majority Leader Chuck Schumer, DN.Y., and House Speaker Nancy Pelosi, California, are trying to push through more than $ 4 trillion in budget spending next month. The country’s top Democrats want a bipartisan $ 1 trillion infrastructure plan and a budget adjustment of $ 3.5 trillion to address issues like climate change and poverty.

Republicans are united in their opposition to the $ 3.5 trillion plan.

The revenue stream could also be an attempt to reassure Conservative Democrat Senator Joe Manchin, who Thursday called on party leaders to “pause” their deliberations on the $ 3.5 trillion bill.

“For my part, I will not support $ 3.5 trillion or even close to that amount of additional spending without clarifying why Congress is ignoring the grave effects of inflation and debt on existing government programs,” wrote Manchin on Wall Street Journal op-ed.

– CNBC’s Ylan Mui contributed to this report.

Categories
Health

J&J names Joaquin Duato as CEO efficient January 3, changing Alex Gorsky

Johnson & Johnson announced on Thursday evening that Joaquin Duato will become the company’s new CEO effective January 3, replacing previous chairman Alex Gorsky.

Duato will also be appointed to the company’s board of directors following his move to the C-suite role. Previously, he was Vice Chairman of the company’s Executive Committee.

“I have had the pleasure to work closely with Alex for many years and I thank him for his outstanding leadership,” said Duato in a statement. “I am pleased that I will continue to benefit from his guidance and his findings in the future.”

Gorsky, who was CEO for nine years and will now serve as Executive Chairman, said in a statement that “the time is right for me personally as I am more focused on my family for family health reasons.”

Joaquin Duato, Executive Vice President and Worldwide Chairman of Pharmaceuticals at Johnson & Johnson on Tuesday, January 31, 2017.

Andrew Harrer | Bloomberg | Getty Images

Johnson & Johnson shares fell nearly 1% during extended trading.

During Gorsky’s time at the helm, J&J faced a wave of lawsuits over its talc-based baby powder and other products and was named in state opioid lawsuits.

Last month, a group of attorneys general reached a $ 26 billion settlement with three of the country’s largest US drug dealers and J&J after claims the companies fueled the deadly opioid epidemic.

According to the settlement proposal, distributors McKesson, Cardinal Health and AmerisourceBergen are expected to pay a total of $ 21 billion, while J&J is expected to pay $ 5 billion over a nine-year period.

J & J’s vaccine was originally touted as a blessing by federal health officials when it was approved by the Food and Drug Administration in late February, as it only requires one dose and can be stored at refrigerator temperatures for months.

Since then, it has suffered from poor perception of its overall effectiveness, concerns about rare side effects, and production delays.

In April, the FDA announced it was adding a warning label to J & J’s Covid vaccine, listing blood clotting as a rare side effect. In July, the FDA announced it was adding another warning to the J&J label, stating that the shot was linked to a serious but rare autoimmune disease called Guillain-Barre Syndrome.

Reuters contributed to this report.

Categories
Entertainment

Simu Liu Slams Disney CEO For Shang-Chi “Experiment” Remark

Simu Liu doesn’t want to Shang-Chi and the legend of the ten rings Considered an “interesting experiment” in light of recent comments from Disney CEO Bob Chapek. During a conference call Thursday, Chapek used the phrase to describe the upcoming 45-day theatrical release of the Marvel film for Wall Street investors. Liu vehemently contradicts the opinion.

“On Shang-Chi“We think it’s actually going to be an interesting experiment for us because it only has a 45-day window for us,” Chapek said aloud diversity. “So the prospect of a Marvel title in that [streaming] Post-theatrical service after 45 days will be another data point to inform about our future promotions on our titles. “

On Saturday, Liu apparently reacted on Instagram and Twitter. “We’re not an ‘interesting experiment,'” he captioned a series of BTS photos from the shoot. “We’re the underdog; the underrated. We’re the ceiling breakers. We’re the celebration of the culture and joy that persists after a competitive year. We’re the surprise. I’m fireproof to making history on September 3rd; YOU WILL MEMBER.”

Chapek’s comments were made to address several of Disney’s recent releases, such as Free guy, which was premiered exclusively in cinemas based on a contractual agreement. He admitted that Shang-Chi “Was planned to be in a much healthier theater environment,” but COVID-19 restrictions have changed the theater experience, as through Black widow, Jungle cruise, and Cruella. But that doesn’t excuse the message behind Chapek’s words. His belief that Shang-Chi‘s release will simply be a “data point” reduced to the film and fans, especially APIA viewers eager to see their community on screen.

Categories
Health

Expedia CEO urges Covid vaccine for all however says it will not be required for workers

Expedia is holding back on a company-wide Covid vaccine mandate even as other large companies begin implementing them, CEO Peter Kern told CNBC on Friday.

“We’re trying to find solutions that are most widely used across our entire workforce, but there are no easy answers. … We all have to learn to live with Covid,” Kern said on Squawk Box. . “

“If we were all vaccinated in the US, we wouldn’t talk a lot about the Delta variant or anything else. But the world is a big place. We won’t vaccinate 8 billion people overnight,” said Kern of the US Census Bureau nearly 7.8 billion, and growing.

The online travel platform CEO’s comments came when United Airlines announced on Friday morning that its 67,000 US employees would have to get vaccinated or risk being fired by October 25th – a first among major US airlines and a move that will likely put pressure on its competitors. Other airlines, including Delta Air Lines, are still choosing to incentivize their employees and customers to get vaccinated instead of requiring them.

“We have offices in 55 countries around the world, there is no one-size-fits-all answer,” said Kern. “I think everyone gets vaccinated and I think companies are trying to find ways to motivate their employees in the right way and we definitely want our employees to be vaccinated too . “

The travel business has been adversely affected by the more contagious Delta variant spreading in the U.S. and around the world, Kern said. “We’ve certainly seen tremendous demand well into the summer and there is still pretty strong demand. But on the fringes, Delta has certainly had an impact.”

Kern said business travel “lagged significantly,” with delayed plans to return to the office likely to add to this trend. However, he believes that Expedia’s business, international and domestic bookings will return to pre-pandemic levels by next summer.

When travel made a comeback in April, Expedia changed its marketing strategy by updating its app and websites to focus more on collaborating with consumers in planning trips rather than just focusing on the number of bookings. The company raised $ 3.2 billion in new capital last year to help cut costs during the height of the pandemic.

“I think you will see that we are investing better, smarter and more organized against our brands,” said Kern. “You will see that our brands are working more clearly together for the common good rather than competing with one another.”

Expedia announced an adjusted loss per share of $ 1.13 for the second quarter after the bell on Thursday. Analysts had expected a loss of 65 cents per share. However, sales of $ 2.11 billion were better than expected. That’s a 273% increase from pandemic-related sales a year ago, but still about 40% less than in the second quarter of 2019 before Covid.

The company’s brands include the namesake Expedia.com as well as Hotels.com, Vrbo, Trivago, Orbitz and Hotwire.

Categories
World News

Augmented actuality agency Nreal targets IPO inside 5 years, CEO says

SHANGHAI — Nreal, a Chinese company making glasses for so-called augmented reality experiences, is looking to go public within five years, its CEO told CNBC.

“We’re thinking this is really a major tech market and really looking forward to what’s going to happen in the next 10 to 15 years. Very exciting – I think its more like ’06, ’07 of the smartphone business,” Chi Xu, CEO of Nreal said.

“We see a lot of good opportunities and, definitely, we’re thinking the market size is going to be massive. And we have this opportunity and we want to take this to the final end.”

He said an initial public offering could come in “less than 5 years.”

The company’s flagship product is a pair of lightweight glasses called Nreal Light, which has been released in a handful of markets including South Korea and Japan. Nreal says its glasses allow users to experience “mixed reality” where digital images are superimposed over the real world.

The Nreal Light connects to a smartphone. One of the immediate uses frees people from being tied to their small smartphone screens.

“Whatever you’re displaying in the cellphone screen in front of you, you put that in front of your face, into a massive screen, and that can be 3D, that can be ultra-high definition,” Xu said.

An attendee tries a pair of Nreal mixed-reality glasses at the MWC Shanghai exhibition in Shanghai, China, on Tuesday, Feb. 23, 2021.

Qilai Shen | Bloomberg | Getty Images

Nreal’s ambitions pit it against technology giants that see a bright future in augmented reality. Apple CEO Tim Cook has called AR the “next big thing” and the iPhone giant is reportedly working on a headset. Facebook, Microsoft, Google and other technology companies are all investing in AR.

But current headsets on the market are expensive and often bulky. Nreal is hoping its portable nature will appeal to consumers. The price varies by market depending on how it is distributed. For example, in Japan the headset costs around $700. But in South Korea, the device can be purchased through a telecom operator’s plan which subsidizes the headset to around $300.

Business model

Nreal has a platform for developers to create apps for the headset’s operating system called Nebula.

“It’s very similar to what Apple has been doing for smartphone,” Xu said. “We offer a platform where people use that for different kinds of experiences and developers — they can deploy, they can develop different content onto the field.”

Apple not only makes money from sales of its iPhones and other hardware but it also gets revenue from commissions off its App Store.

Nreal has some notable backers. Kuaishou, the short-video platform in China and iQiyi, a video streaming service, are among the company’s investors. Xu said Nreal would be working with both Kuaishou and iQiyi.

“As we mentioned, not only are we going to provide the hardware. We want to bundle different services with the glasses. So take video for example, whether it’s a long video or short video. We’re thinking glasses are a much better terminal to experience the video in,” the CEO said.

“So that’s why we’ll be working with those giants, really working on the new interface.”

Categories
World News

Renewable hydrogen can journey by means of present pipelines, CEO says

The CEO of Italian infrastructure giant Snam outlined a vision for the future of hydrogen on Friday, saying the “beauty” of it is that it can be easily stored and transported.

Speaking to CNBC’s Squawk Box Europe, Marco Alverà spoke about how current systems would be used to facilitate the delivery of hydrogen from renewable sources as well as biofuels.

“If you turn up your heating in Italy now, the gas will flow in pipelines from Russia to Siberia,” he said.

“Tomorrow we will have hydrogen produced in North Africa, in the North Sea, with solar and wind resources,” said Alverà. “And this hydrogen can travel through the existing pipeline.”

Alvera said Snam tested various mixing percentages – including up to 100% hydrogen – in existing pipes and it worked.

“So this is an energy transition that uses the infrastructure we have,” he said. “And the very good news is that this new renewable energy will cost less than the existing fossil fuel, namely [a] real breakthrough. “

Read more about clean energy from CNBC Pro

Described by the International Energy Agency as a “versatile energy carrier”, hydrogen has a wide range of possible uses and can be used in sectors such as industry and transport.

It can be made in a number of ways. One method involves the use of electrolysis, where an electrical current breaks water into oxygen and hydrogen.

When the electricity used comes from a renewable source such as wind or sun, some call it green or renewable hydrogen.

Currently, the vast majority of hydrogen production is fossil fuel based and green hydrogen is expensive to produce.

Future challenges

In an interview with CNBC on Friday, Francesco Starace, CEO of Enel, said that “there is no competition for capital between hydrogen and renewables”.

“Hydrogen is a niche today, and it’s a niche that needs to evolve into a commercial standard and … a large, competitively-priced industry,” Starace said, signaling that such a shift would likely take 10 years.

“So it’s a big expense in research and development, it’s a big expense in prototypes, a big expense in pilot plants, but nothing compared to what’s going on today on the very large and competitive battlefield of renewable energies.”

While the potential role of hydrogen in the future is excited, there are still challenges.

A World Energy Council briefing earlier this week said low-carbon hydrogen “is not cost-competitive with other energy sources in most applications and in most locations.”

It is unlikely that the situation will change unless there is “significant support to bridge the price gap”.

The analysis, which was carried out in collaboration with PwC and the US Electric Power Research Institute, raised the question of where the funding for such support should come from, but also pointed to the increasing awareness of the industry and the associated positive effects.

Categories
Health

Novartis CEO says Covid-related physician go to delays seemingly impacting most cancers analysis charges

The health-care system is still seeing lower rates of diagnoses for certain conditions after the coronavirus pandemic kept non-Covid patients away from the hospital early on, Novartis CEO Vasant Narasimhan told CNBC on Wednesday.

“I think the signals that were sent that ultimately asked patients to stay away from the emergency room, stay away from hospitals, sent a very powerful message to patients not to get the care that they needed,” Narasimhan said on “Closing Bell.” “It may have been appropriate given the public health emergency, but over time what that does is it creates a significant need for better treatments for these patients.”

Narasimhan, who joined Novartis in 2005, said that while trends are positive, lower rates of diagnoses in areas such as cardiovascular disease and oncology remain. For the latter, he said diagnoses are still 30% to 40% lower than pre-Covid-19 levels. Novartis makes cancer treatments.

Nearly 1 in 3 Americans between the ages of 50 and 80 delayed an in-person medical visit last year due to worries about exposure to Covid, according to a poll from the National Poll on Healthy Aging based at the University of Michigan Institute for Healthcare Policy and Innovation. The poll, taken in January, found that 24% of people with cancer and 30% of people with heart conditions had delayed at least one in-person visit.

“Cancer patients that are diagnosed later tend to have worse outcomes, similarly for cardiovascular disease patients that don’t get the therapies that they need,” Narasimhan said. “That in turn creates more burden on the health-care systems over time.”

As Covid cases increase in the U.S. and around the world due to the highly transmissible delta variant, Narasimhan hopes lessons from the early stages of the health crisis have been learned. “I think it’s critical now, this time around, we ensure patients can maintain their care even as the pandemic ebbs and flows over the coming months,” he said.

“We remain optimistic that even as we go through various waves of Covid that the health-care systems have learned that we need to maintain care for noncommunicable diseases, other chronic diseases,” he added.” “Otherwise in effect we create another epidemic, a syndemic so to speak, of these other diseases.”

On Wednesday, Novartis beat analyst expectations for second-quarter revenue and earnings. Narasimhan said the Swiss drugmaker witnessed a resurgence in demand across many therapeutic areas, and noted the company had 9% growth in sales and 13% growth in operating income. 

Novartis is currently involved in manufacturing the Pfizer-BioNTech Covid vaccines, and is assisting CureVac in making vaccines, as well. Novartis also produces monoclonal antibodies to treat Covid for partner companies,” Narasimhan said. “We’re doing a lot, but also ready to do more if needed.”

Categories
Health

Delta CEO says delta Covid variant has had no impression on bookings

A Delta Airlines Boeing 757-251 approaches Washington Ronald Reagan National Airport (DCA) in Arlington, Virginia on February 24, 2021.

Daniel Slim | AFP | Getty Images

The spread of the highly transmissible delta variant of Covid-19 hasn’t hurt Delta Air Lines’ bookings, CEO Ed Bastian said Wednesday.

“We haven’t seen any impact at all from the variant,” Bastian said in an interview with CNBC’s “Squawk Box,” shortly after reporting better-than-expected quarterly revenue.

Other airline CEOs including those of American Airlines and United Airlines have also said that domestic leisure bookings have largely rebounded to 2019 levels recently and that business travel is also recovering, though at a much slower pace.

The Centers for Disease Control and Prevention last week said the delta Covid variant became the dominant strain in the U.S. earlier this month, sparking concerns about its rapid spread, particularly among the unvaccinated.

But summer travel and future travel bookings remain strong. Domestic leisure travel is at — “if not beyond” — levels last seen in 2019, before the pandemic, Bastian said.

“As the news of the variant’s spreading, we haven’t seen any slowdown at all,” Bastian said, citing bookings 60 to 90 days in advance. “We’re learning to live with this.”

Bastian added that 72% of Delta’s employees are vaccinated and a “vast majority” of surveyed customers say they have also been vaccinated.

Categories
Health

CRISPR gene enhancing may attain sufferers ‘very quickly’: Intellia CEO

Following a breakthrough trial where gene-editing technology CRISPR completed its first systematic delivery as medicine to a human body, Intellia Therapeutics CEO John Leonard said he hopes the gene therapy could be made available to patients “very, very soon.”

“These approaches are subjected to the standard sorts of clinical trials that any drug or gene therapy would be studied under, so we’re in the earlier stages of that,” Leonard said on CNBC’s “Closing Bell” on Thursday afternoon.

He added that over the next few years, the company expect the medical technology to be subjected to standard reviews, “but our hope is that this will be available to patients very, very soon.”

CRISPR, or clustered regularly interspaced short palindromic repeats, effectively cuts genomes and slices DNA to treat genetic diseases.

The latest development, the result of a trial between Intellia and biotech company Regeneron, treated a rare disease after being given as an IV infusion. Previously, other applications of the CRISPR technology had been limited to ex vivo therapy, or where cells are removed from the body for genetic manipulation in a laboratory and then reintroduced to the body.

“What’s particularly exciting about that is we were able to completely inactivate that gene and see that in the clinical effects of the patient, so a major advance in the gene editing space,” Leonard said.

Heart, diabetes and broad disease implications

CRISPR has broad applications, and Leonard said there is a lot of work being done to target some of the most common diseases and causes of death, such as heart disease and diabetes.

“The challenge is getting into those particular genes that cause disease, so we started in the liver, which is an area where there are many problems with disease-causing genes, and it’s been shown that we can reach that very, very successfully,” Leonard said. “There’s other tissues after that that we’re pursuing, especially the bone marrow, where a long list of blood-borne-type diseases can be addressed.”

A key for CRISPR is targeting diseases that are monogenic, or caused by one particular gene, allowing this type of gene-editing therapy to be successful, Leonard said. Other diseases that are polygenic, such a cancers or autoimmune diseases, will be “more difficult to tackle,” he added.

A researcher watches the CRISPR/Cas9 process through a stereomicroscope at the Max-Delbrueck-Centre for Molecular Medicine.

picture alliance | picture alliance | Getty Images

The new treatment is still in the early stages and it has not been priced yet, but as it develops, Leonard said he believes it will be “very valuable for patients and probably resource sparing for the health care system overall.”

“It really comes down to the some of the advantages with single application where literally it’s a one-and-done therapy,” Leonard said. “We expect over time this will be generally very, very favorable in the economics of this entire field.”

Jennifer Doudna, who was awarded the 2020 Nobel Prize in chemistry for her work on CRISPR gene editing and is the co-founder of Intellia, recently told the CNBC Evolve Global Summit that cost is a significant challenge, and in the case of sickle cell anemia, where CRISPR has had early success, treatment can still be $2 million.

“That is clearly not a price point that will make this available to most people that can benefit from it,” she said. Innovations in delivery of CRISPR may help lower cost, but Doudna also said that the medical field needs to figure out how to “scale the molecule production so that we reduce costs.”

She told CNBC the evolution of the technology from the publication of her early work to clinical trials showing it to be effective in treating diseases in less than 10 years represents, “One of the fastest rollouts I think of technology from the fundamental, initial science to an actual application.”

“It’s largely because the technology comes at a moment when there’s enormous demand for genome editing, as well as a lot of knowledge about genomes,” Doudna said.

Categories
Health

Eli Lilly CEO says drugmaker will preserve trying to lower insulin prices

An Eli Lilly & Co. logo is seen on a box of insulin medication in this arranged photograph at a pharmacy in Princeton, Illinois.

Daniel Acker | Bloomberg | Getty Images

Eli Lilly CEO David Ricks said he welcomes new competition from Walmart, even as the retailer undercuts the drugmaker’s prices on fast-acting insulin.

Walmart announced Tuesday that it will sell a lower-price version of the notoriously expensive diabetes drug, starting this week.

“Any efforts to smash through that and deliver better value to patients, I’m for,” Ricks said in an interview Tuesday on CNBC’s “Squawk on the Street.”

Walmart developed the less expensive version of analog insulin with Novo Nordisk. The fast-acting insulin will cost about $73 for a vial or about $86 for a package of prefilled insulin pens. It will be available exclusively at Walmart and Sam’s Club for adults and children with a prescription.

Insulin has become a focal point in lawmakers’ debate over soaring drug prices — especially since it is a 100-year-old medication and one that can be lifesaving for millions of Americans diagnosed with diabetes. Eli Lilly is among the companies that have faced pushback for its prices by politicians on both sides of the aisle, including former President Donald Trump.

Ricks said the company’s leaders “welcome anyone who wants to lower the price of insulin” — including the big-box retailer.

“We always look at new solutions ourselves, and this is an interesting development and we’ll look at further options,” he said. “If we can reach one more patient with more affordable insulin, we’re going to try to do that.”

Ricks said Eli Lilly continues to seek ways to reduce costs for people with diabetes. He pointed to two related efforts: The launch of a half-price, generic version of insulin, called insulin lispro, in early 2019 and the cap on out-of-pocket cost for insulin at $35 per month, which began as many Americans struggled with finances during the coronavirus pandemic.

Those moves, in part, were a response to fierce criticism by lawmakers and a subpoena by the state of New York.

Eli Lilly’s generic version costs nearly twice the price of Walmart’s at $137.35 per vial.

Over the past 20 years, the number of adults diagnosed with diabetes has more than doubled, according to the Centers for Disease Control and Prevention. About 34.2 million U.S. adults have the disease, which ranks as the seventh-leading cause of death in the country, the CDC said.